Merus Price to Free Cash Flow Ratio 2016-2021 | MRUS

Historical price to free cash flow ratio values for Merus (MRUS) since 2016. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merus Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-19 26.52 0.00
2021-09-30 22.00 $-1.58 0.00
2021-06-30 21.07 $-1.38 0.00
2021-03-31 20.89 $-1.37 0.00
2020-12-31 17.53 $-2.78 0.00
2020-09-30 12.00 $-2.70 0.00
2020-06-30 16.09 $-2.94 0.00
2020-03-31 12.10 $-2.98 0.00
2019-12-31 14.08 $-2.70 0.00
2019-09-30 17.82 $-2.46 0.00
2019-06-30 14.65 $-2.61 0.00
2019-03-31 14.77 $-1.97 0.00
2018-12-31 14.00 $-2.15 0.00
2018-09-30 19.74 $-2.14 0.00
2018-06-30 22.76 $-2.16 0.00
2018-03-31 18.53 $-2.64 0.00
2017-12-31 19.40 $-2.25 0.00
2017-09-30 19.87 $-2.73 0.00
2017-06-30 15.85 $-1.95 0.00
2017-03-31 24.39 $-2.58 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.040B $0.030B
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75